SUVENPHAR

Cohance Lifesciences Ltd.

NSE: COHANCE

BSE: 543064

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

444.35-19.6 (-4.22%)

12 Aug, 3:30 PM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

43.5 / 100

Value Score

15.5 / 100

Price Momentum Score

28.0 / 100

QVM Score

11.7 / 100

Key Metrics

Market Cap

17750.60

P/E (TTM)

167.10

P/B

4.54

P/S (TTM)

8.29

EV/EBITDA

56.38

CAPE (5Y)

41.31

ROE (TTM)

6.39

ROCE (TTM)

7.31

ROA (TTM)

4.09

Avg 3Y ROE

12.18

Earnings 3Y CAGR

-45.08

Sales 3Y CAGR

16.65

Sales 5Y CAGR

15.65

Debt/Equity

0.10

Consensus TP

440.00

Strong Buy %

12.50

Promoter Holding

57.49

Pledged %

94.56

Stock Analysis

Fundamental analysis overview of Cohance Lifesciences Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 1.22% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 41.24% for 12-month ended 30 Jun 2026 and the growth was 29.31 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 11.93

Value 41.24

-42.894040.18

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.1 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.06 in the last 1 year

What is Debt to Equity?

Company's earnings are of high quality

Earnings quality score of 74.1 indicates that the company's earnings are of high quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

74.1 / 100

Negative

Expensive and at a premium to industry median P/E

PE TTM of 167.1 indicates that the stock is expensive on a standalone basis and is at a 453.13% premium to industry median P/E

What is P/E Ratio?

Median: 30.21

Value 167.1

0.33276.01

Weak price momentum

Price Momentum score of 28.0 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term

What is Price Momentum score?

28.0 / 100

Low and declining ROE

The company reported low ROE of 6.39% for 12-month ended 30 Jun 2026 and ROE declined by -790 bps from 1 year ago

What is ROE (FY)?

Low and declining operating margin

The company reported low operating margin of 5.81% for 12-month ended 30 Jun 2026 and operating margin declined by -1385 bps from 1 year ago

What is Operating profit margin?

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -70.49% for 12-month ended 30 Jun 2026 and the growth was 79.26 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Cohance Lifesciences Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Cohance Lifesciences Ltd. Shareholding Pattern

Quarterly breakdown of Cohance Lifesciences Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	50.10	50.10	50.10	50.10	50.10	66.41	57.49	57.49	57.49	57.49
Indian Promoter	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	60.00	9.90	9.90	-	-	-	-	-	-	-	-	-	-
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50.10	50.10	50.10	50.10	50.10	50.10	50.10	66.41	57.49	57.49	57.49	57.49
Institutions	8.19	8.16	9.14	10.70	12.45	13.38	13.84	14.18	15.12	15.45	18.45	19.46	20.90	20.13	24.16	26.09	26.79	27.23	27.65	27.53	27.66	18.64	27.34	27.60	27.39	26.60
Mutual Funds / UTI	2.34	2.89	3.54	3.29	4.30	4.47	4.94	5.24	5.91	6.32	8.28	8.97	8.56	9.12	12.15	13.40	15.26	14.78	14.12	13.15	13.04	8.90	16.49	17.36	18.57	18.21
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.24	2.23	2.26	0.11	1.39	1.89	1.57	2.09	2.53	3.20	3.26	2.27	3.95	3.94	3.13	1.77
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
FII	4.24	3.55	4.15	6.04	6.93	7.93	8.03	8.25	8.56	8.49	7.58	8.10	9.47	9.50	10.01	10.14	9.54	9.80	10.70	10.84	11.05	7.23	6.51	6.01	5.59	6.50
Other Institutions	1.61	1.73	1.45	1.36	1.22	0.98	0.88	0.69	0.65	0.63	0.35	0.17	0.61	1.40	0.60	0.65	0.41	0.55	0.30	0.32	0.30	0.23	0.37	0.27	0.09	0.11
Non-Institution	31.81	31.84	30.86	29.30	27.55	26.62	26.16	25.82	24.88	24.55	21.55	20.53	19.10	19.87	15.84	13.92	23.10	22.67	22.25	22.37	22.23	14.95	15.17	14.92	15.12	15.92
Bodies Corporate	3.14	3.21	2.78	2.65	2.48	2.31	2.17	2.01	1.97	1.94	1.89	1.72	1.72	2.55	2.38	1.43	11.10	11.15	11.08	11.17	11.13	7.41	7.83	7.27	7.19	7.32
Others (incl. Retail) No. of shareholders	28.67 60,039	28.63 64,483	28.08 76,786	26.65 75,085	25.07 74,345	24.31 91,692	23.99 95,407	23.81 85,262	22.91 84,432	22.61 84,749	19.66 81,660	18.81 78,606	17.38 72,113	17.32 71,369	13.46 72,904	12.49 69,279	12.00 68,195	11.52 65,047	11.17 68,549	11.20 83,314	11.10 85,364	7.54 79,995	7.34 74,346	7.65 81,003	7.93 84,452	8.60 98,407

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Smallcap 50	0.89%	47 / 49
2	Nifty MNC	0.66%	30 / 30
3	Nifty Smallcap 250	0.32%	122 / 249
4	Nifty Total Market	0.03%	390 / 749
5	Nifty 500	0.03%	368 / 499

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Cohance Lifesciences Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Jusmiral Holdings Limited Promoter	September-2025	Market Sale (Disposal) 19th Sep 2025	33.08 %	₹ 906.00	3.41 cr	₹ 3093.81 cr
Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri Director	August-2025	Market Sale (Disposal) 28th Aug 2025	0.19 %	₹ 880.30	6.00 lac	₹ 52.82 cr
JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED in its capacity as sole Trustee of the Jasti Family Trust Promoter	September-2023	Off Market (Disposal) 30th Sep 2023	60.00 %	₹ 495.00	12.75 cr	₹ 6313.08 cr
PADMAJA J.A.S Directors Immediate Relative	August-2023	Market Sale (Disposal) 14th Aug 2023	0.01 %	₹ 501.77	28.00 k	₹ 1.40 cr
PADMAJA J.A.S Directors Immediate Relative	February-2023	Market Sale (Disposal) 17th Feb 2023	0.01 %	₹ 482.25	7.00 k	₹ 33.76 lac

Corporate Actions

History of Cohance Lifesciences Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 1/share
Record date: 12th Sep 2022Ex-date: 9th Sep 2022
Announced on: 29th Aug 2022
Dividend₹ 5/share
Record date: 12th Sep 2022Ex-date: 9th Sep 2022
Announced on: 2nd Sep 2022
Dividend₹ 1/share
Record date: 17th May 2022Ex-date: 13th May 2022
Announced on: 2nd May 2022
Dividend₹ 1/share
Record date: 17th May 2022Ex-date: 13th May 2022
Announced on: 2nd May 2022
Dividend₹ 1/share
Record date: 16th Feb 2022Ex-date: 15th Feb 2022
Announced on: 1st Feb 2022

Company Profile

Overview of Cohance Lifesciences Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based company focused on global contract development and manufacturing organization (CDMO) platform. The Company specializes in providing end-to-end solutions across the molecules lifecycle from early-stage development...

Key personnel

Mr. Yann Dherve

Chief Executive Officer

Mr. Sisir Kumar Mishra

Compliance Officer, Company Secretary

Ms. Cyndrella Carvalho

Investor Relation Officer

Ms. Cyndrella Carvalho

Investor Relation Officer

Ms. Cyndrella Carvalho

Investor Relation Officer

Ms. Cyndrella Carvalho

Investor Relation Officer

Mr. Vivek SharmaD

Executive Chairman of the Board

Mr. Himanshu AgarwalD

Chief Financial Officer, Whole-Time Director

View all

Incorporated on

06 Nov 2018

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

09 Mar 2020

Free Float

13,78,89,454

Website

https://www.cohance.com/

Phone no.

+914023549414

Address

202, A-Wing, Galaxy Towers, Plot No-1, Hyderabad Knowledge City,, TSIIC, Raidurg, Serilingampally,, RANGAREDDY, 500081, India

Frequently Asked Questions

What is the current share price of Cohance Lifesciences Ltd.?

The current share price of Cohance Lifesciences Ltd. is ₹ 444.35 as of 12 Aug 2026.

What is the market capitalisation of Cohance Lifesciences Ltd.?

The market capitalisation of Cohance Lifesciences Ltd. stands at ₹ 17,750.60 Cr.

What is the PE ratio of Cohance Lifesciences Ltd.?

The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd. is 167.10 as of the latest trailing twelve months data.

What is the ROE and ROCE of Cohance Lifesciences Ltd.?

Cohance Lifesciences Ltd. has a Return on Equity (ROE) of 6.39% and a Return on Capital Employed (ROCE) of 7.31% as per the latest financial reports.

What is the 52-week high and low of Cohance Lifesciences Ltd.?

The 52-week high of Cohance Lifesciences Ltd. is - and the 52-week low is -.

What is the dividend yield of Cohance Lifesciences Ltd.?

The dividend yield of Cohance Lifesciences Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Cohance Lifesciences Ltd.?

Foreign Institutional Investors (FII) hold 6.50%, Domestic Institutional Investors (DII) hold 19.98% and retail/public investors hold 8.60% of Cohance Lifesciences Ltd. shares.

What sector does Cohance Lifesciences Ltd. belong to?

Cohance Lifesciences Ltd. operates in the Healthcare sector. 37.5% of analysts have a Buy or Strong Buy rating on Cohance Lifesciences Ltd. with a consensus target price of ₹ 440.00, implying 5.16% downside from current levels.

What is the beta of Cohance Lifesciences Ltd.?

The beta of Cohance Lifesciences Ltd. is 0.80, indicating its price volatility relative to the broader market. Over the past 1 year, Cohance Lifesciences Ltd. has delivered an absolute return of -52.63%.

What is the RSI of Cohance Lifesciences Ltd.?

The 14-day Relative Strength Index (RSI) of Cohance Lifesciences Ltd. is 65.85, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Cohance Lifesciences Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Cohance Lifesciences Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Corporate Actions

Company Profile

Holdings and Presence